Full-Time

Associate Director

Multiple Teams

Formation Bio

Formation Bio

51-200 employees

AI-driven platform accelerates clinical-stage drug development

Compensation Overview

$213.5k - $267k/yr

+ Equity

Boston, MA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid schedule requires three days per week in the office. Applicants must reside in or be willing to relocate to the listed hiring hubs.

Bachelor's, Master's, PhD

Category
Data & Analytics (1)
Required Skills
LLM
Data Science
Machine Learning
Data Engineering
Electronic Health Records (EHR)

Get referred to Formation Bio

See people who can refer or advise you

Requirements
  • A Bachelor of Science or Master of Science degree in biomedical informatics, computational sciences, epidemiology, or a related quantitative field.
  • At least five years of industry experience working directly with real-world data, including electronic health records/electronic medical records, claims, registries, or linked biobank data, in pharma, biotech, health tech, or consulting, with at least two years in people management.
  • Strong data engineering proficiency in pipelines, ingestion frameworks, data models, and data lakes/marts, combined with working knowledge of biological and medical ontologies including ICD, SNOMED CT, MedDRA, RxNorm, and ATC, and harmonization standards, particularly OMOP CDM.
  • Experience with real-world data procurement and vendor management, including evaluating data providers, negotiating agreements, and integrating new data assets.
  • Ability to deliver real-world-data-derived insights across drug development use cases such as trial design, epidemiology, comparative effectiveness, and label expansion, with familiarity across the development lifecycle from target selection through post-market.
  • Proficiency with modern artificial intelligence and machine learning tools, including large language models, and their applications in data engineering and harmonization workflows.
  • Ability to translate complex data infrastructure concepts for clinical, scientific, and executive audiences.
Responsibilities
  • Lead the Real-World Data Intelligence function within Data Science, owning data strategy, sourcing, and delivery of analysis-ready datasets.
  • Architect and maintain infrastructure including pipelines, ingestion workflows, data models, and data lakes/marts across electronic health records/electronic medical records, claims, registries, and genomics-linked cohorts.
  • Drive adoption and extension of harmonization frameworks such as OMOP CDM across heterogeneous data sources, using artificial intelligence and machine learning tools for entity resolution, ontology mapping, data quality monitoring, and automated harmonization.
  • Manage real-world data vendor relationships end-to-end by evaluating providers, negotiating data use agreements, brokering new partnerships, and integrating acquired datasets into the platform.
  • Partner with Data Science, Clinical Development, Business Development, and Engineering teams to define real-world data use cases and productize ad hoc pipelines into scalable, production-grade systems.
  • Foster data quality rigor, documentation, and reproducibility across real-world data assets.
Desired Qualifications
  • A PhD in biomedical informatics, epidemiology, computational biology, or a related field.
  • Experience with large-scale biobank and genomics-linked real-world data platforms such as UK Biobank, FinnGen, and All of Us, including building real-world data infrastructure that influenced drug acquisition, licensing, or portfolio decisions.
  • Familiarity with biomedical data modalities such as scientific literature mining, omics datasets, and molecular data integration, and with data science and analytics methodologies applied to real-world data, including causal inference, trial simulation, and propensity score methods.
  • Experience transitioning data infrastructure from research or ad hoc systems to production-grade systems in regulated environments.
  • Experience working at the intersection of data engineering, data science, and business strategy in pharma or biotech.

Formation Bio uses an AI-driven platform to speed up drug development by focusing on clinical-stage assets. It acquires and advances these assets using flexible financing structures, aiming to shorten timelines and cut costs for bringing new drugs to market. The core product is the proprietary AI tools that help with drug selection, development planning, and improving overall efficiency, enabling partnerships and successful commercialization with pharmaceutical and biotech companies. Compared with competitors, Formation Bio combines a data-powered approach with adaptable financing and asset acquisition strategies to move assets forward quickly and cost-effectively. The goal is to make treatments more accessible and affordable by accelerating development and enabling faster, more predictable commercialization through AI-enhanced decision making and flexible funding options.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Get referred to Formation Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 29, 2026 Kenmare Bio in-licensed FHND5032, expanding autoimmune pipeline depth.
  • June 9, 2026 BLKR201 dosing created a near-term early-2027 catalyst.
  • Formation Bio raised $372 million in Series D, supporting pipeline and AI expansion.

What critics are saying

  • BLKR201 remains unproven; early-2027 readout determines whether Formation Bio justifies its model.
  • FHND5032 and BLKR201 concentrate value in two assets; one failure crushes leverage.
  • Without repeat clinical wins, Formation Bio becomes a costly AI wrapper around failed bets.

What makes Formation Bio unique

  • Formation Bio pairs AI software with clinical asset ownership, not pure-platform licensing.
  • July 22, 2026 hire Michael Ehlers strengthens translational and clinical development credibility.
  • June 9, 2026 BLKR201 entered Phase 1 five months after in-licensing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
PR Newswire
Jul 22nd, 2026
Formation Bio appoints Michael Ehlers as CSO to lead R&D strategy

Formation Bio has appointed Michael D. Ehlers as Chief Scientific Officer and Head of R&D. Ehlers will oversee portfolio strategy and advancement, from translational sciences through clinical development, and guide the scientific direction of Formation Bio's AI platform. Ehlers joins from MPM BioImpact, where he was an Entrepreneur Partner. He previously served as Executive Vice President of R&D at Biogen and held senior positions at Pfizer. Throughout his career, programmes under his leadership have produced six approved drugs spanning five indications and four drug modalities, with more than 40 programmes advanced into the clinic. Formation Bio is an AI-native pharma company that acquires clinical-stage assets and accelerates them through development using its proprietary AI platform.

PR Newswire
Jun 9th, 2025
Formation Bio Announces First Class Of Entrepreneurs In Residence To Drive Pipeline Growth And Strategic Partnerships

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei, Ph.D., Minji Kim Ph.D, MBA, John Taylor, M.S., and Anthony S. Walsh, D.Phil, These seasoned dealmakers will work closely with Chief Business Officer David Steinberg to expand the company's business development capabilities and further its mission to bring high-potential treatments to patients faster. Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement. The company's AI platform supports this lifecycle end-to-end—from asset identification and development strategy to execution of clinical trials aimed at greater speed and higher probability of success

Intelligence360 News
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

FinSMEs
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

HIT Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities